1. Among patients hospitalized with severe COVID-19 and hyperinflammation, treatment using the anti-interleukin-1β antibody canakinumab, compared with placebo, did not significantly increase the likelihood of survival without invasive mechanical ventilation at day 29.
2. These findings for canakinumab vs placebo were also consistent for the secondary outcome of COVID-19-related mortality...
1. In this secondary analysis of data from the CANTOS trial in 2017, canakinumab significantly reduced the incidence of anemia in patients with a history of myocardial infarction.
2. Among participants with baseline anemia, those who received canakinumab had significantly higher hemoglobin levels versus placebo.
Evidence Rating Level: 3 (Average)
1. Use of canakinumab was associated with reduced risk for gout attacks.
2. Canakinumab administration did not result in changes to serum uric acid levels.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Gout is the most common inflammatory arthritis in adults, and its prevalence has increased substantially over the past several decades....